<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102649">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02090660</url>
  </required_header>
  <id_info>
    <org_study_id>12-5454</org_study_id>
    <nct_id>NCT02090660</nct_id>
  </id_info>
  <brief_title>Technique for Localization of Pulmonary Nodules Using Spy Thoracoscope System</brief_title>
  <official_title>Feasibility of a Novel Minimally Invasive Technique for Localization of Pulmonary Nodules Using the Spy Thoracoscope System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novadaq Technologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the feasibility of the novel Indocyanine Green (ICG) fluorescence
      localization technique with a Laser fluorescence thoracoscope system.

      The primary objective of this study is to prove the validity and safety of our novel
      fluorescent localization method with utilized  ICG and novel near infra-red fluorescence
      videoscope system.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Compare incidence of Adverse Events (AE) occurrence due to ICG injection with micro-coil placement versus overall AE occurrence for micro-coil placement alone.</measure>
    <time_frame>Within 4 hours of ICG injection</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>VATS wedge lung resection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ICG Localization with Spy thoracoscope localization</intervention_name>
    <arm_group_label>VATS wedge lung resection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient scheduled for a VATS wedge lung resection using CT guided micro-coil lung
             implantation for the localization of the lung lesion.

        Exclusion Criteria:

          -  Any patients with an allergy to iodine, shellfish, or cough mixture, betadine or
             other iodine contrast agents.

          -  Pregnant or potentially pregnant women.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazuhiro Yasufuku, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandria E Grindlay</last_name>
    <phone>416-581-7486</phone>
    <email>alexandria.grindlay@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frances Allison</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>5446</phone_ext>
    <email>frances.allison@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Health Network: Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kazuhiro Yasufuku, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>March 14, 2014</lastchanged_date>
  <firstreceived_date>March 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
